Clinical Trials Logo

Clinical Trial Summary

Nimotuzumab, as one new agent used in advanced esophageal carcinoma, has been shown to be effective and safe in some studies with head-neck cancers. Advanced esophageal carcinoma have poor prognosis and majority of patients resistant to chemotherapy in China. In the investigators phase II clinical trial proceeded before,the combination of paclitaxel with cisplatin showed good tolerance and efficacy to esophageal carcinoma. The investigators then initiated a prospective phase II clinical trial with Nimotuzumabplus paclitaxel/cisplatin as the 1st line treatment in advanced esophageal carcinoma to observe the efficacy and safety of the combination.


Clinical Trial Description

n/a


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01336049
Study type Interventional
Source Peking University
Contact xiaodong zhang, MD
Phone 86-01-88196175
Email zxd0829@yahoo.com.cn
Status Recruiting
Phase Phase 2
Start date March 2011

See also
  Status Clinical Trial Phase
Terminated NCT03223662 - Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy Phase 2
Terminated NCT01627379 - Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer Phase 3
Recruiting NCT05945823 - Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors Phase 2
Recruiting NCT04804696 - Toripalimab With Paclitaxel and Cisplatin as Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma Phase 2
Recruiting NCT02016287 - Sequential Paclitaxel Chemotherapy and Radiotherapy as 1st Line Treatment for Elderly Esophageal Squamous Cell Cancer Phase 2
Recruiting NCT02016274 - Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as 1st Line Treatment for Esophageal Squamous Cell Cancer Phase 2
Active, not recruiting NCT01351103 - A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Phase 1
Recruiting NCT01993784 - Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma. Phase 1/Phase 2